Since comprehensive analysis of the mammalian genome revealed that the majority of genomic products are transcribed in long non-coding RNA (lncRNA), increasing attention has been paid to these transcripts. The applied next-generation sequencing technologies have provided accumulating evidence of dysregulated lncRNA in cancer. The implication of this finding can be seen in many forms and at multiple levels.
Since comprehensive analysis of the mammalian genome revealed that the majority of genomic products are transcribed in long non-coding RNA (lncRNA), increasing attention has been paid to these transcripts. The applied next-generation sequencing technologies have provided accumulating evidence of dysregulated lncRNA in cancer. The implication of this finding can be seen in many forms and at multiple levels.
With impacts ranging from integrating chromatin remodeling complexes to regulating transcription and post-transcriptional processes, aberrant expression of lncRNA may have repercussions in cell proliferation, tumor progression or metastasis.
lncRNA may act as enhancers, scaffolds or decoys by physically interacting with other RNA species or proteins, resulting in a direct impact on cell signaling cascades.
Even though their functional classification is well-established in the context of cancer, clearer characterization in terms of their phenotypic outputs is needed to optimize and identify suitable candidates that enable the development of new therapeutic strategies and the design of novel diagnostic approaches. The present article aims to outline different cancer-associated lncRNA according to their contribution to tumor suppression or tumor promotion based on their most current functional annotations.
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| INTRODUCTION
For several decades, non-protein-coding DNA was referred to as junk DNA, a term that has become obsolete. The large-scale genomic projects FANTOM and ENCODE revolutionized the study of the human genome and elucidated that, in fact, 80% of the genome harbors biochemical marks of active transcription and that solely 2% of the genome is restricted to protein coding. 1, 2 Thereby, the FANTOM and ENCODE platforms highlighted the pervasive way in which the genome is transcribed. Full-length cDNA sequencing profiles revealed new transcripts and new coding genes. Further optimization facilitated the detection of low-abundance transcripts that corresponded to antisense RNA and long non-coding RNA (lncRNA). 3 With the observation of a gradually increased prevalence of noncoding DNA regions in superior organisms, together with recent genome-wide annotations in which 58 648 lncRNA account for 68% of the human transcriptome, the lncRNA class has gained more attention. (ii) modulators of mRNA processing, post-transcriptional control and protein activity; and (iii) organization of nuclear domains.
Despite the elucidation of potential mechanistic roles, the biological relevance of the vast majority of lncRNA remains uncertain. In fact, their intricacy relies not only on their functional switch but also in their ability to be tissue/cell-specific. Furthermore, lncRNA that are detected overall with fewer than 1 copy per cell may appear abundant in certain types of cells or even in specific nuclear compartments, adding yet another layer of complexity. 3 Given their sophisticated nature, lncRNA harbor the ability to be tissue-specific, cell-specific or even compartment-specific. As
Adriaens et al 7 clearly describe in their article, lncRNA may be best considered to be fine-tuners rather than crucial players.
Hence, it is not surprising to find a direct implication of lncRNA in processes such as development or disease. Specifically, in cancer, increasing evidence has strengthened the notion that lncRNA exert cooperative functions to tumor suppression or tumorigenesis. 
| THE LON G NON-CODIN G RNA CODE IN CANCER
The accumulation of genetic and epigenetic alterations results in an extreme form of somatic mosaicism that may lead to cancer. 8 The history of cancer has been ever-evolving, and the fact remains that cancer is a complex disease that certainly demands a complex understanding. Heretofore, the majority of causative evidence for cancer occurrence and progression has been associated with protein-coding regions. Nonetheless, ultraconserved non-coding sequences are commonly found to be deregulated in cancer. 9 For instance, single nucleotide polymorphisms (SNP) are among the high-risk alterations associated with cancer occurrence; interestingly, 85% of SNP are annotated in noncoding regions and linked to disease development. 10 These abnormalities have an impact on lncRNA, which display altered expression and disrupted functions with subsequent deregulation of their targets.
| TUMOR SUPPRESSORS
Most likely, the most notorious gene in cancer research is the tumor suppressor p53 (p53). It works as a transcription factor and activates the expression of multiple genes related to cell cycle arrest and apoptosis. Cellular stress or oncogenic signaling can trigger the activation of p53 through multiple post-translational modifications, and its consequent accumulation in the nucleus substantially increases its detection; however, at normal conditions, its levels are barely detectable. 11, 12 Several lncRNA are included among the network of p53-transcriptionally activated genes ( Table 1 ).
The lncRNA activator of enhancer domains (LED) has been shown to be involved in a win-win relation with p53. While LED is transcriptionally induced by the same p53, it contributes to the regulation of p53 enhancer-derived transcripts ( Figure 1A ). Figure 1B ). 15 In cervical tumors, MEG is conversely related to tumor size and lymphatic metastasis, indicating its strong role as a tumor suppressor and as a potential therapeutic candidate. 16 Likewise, downregulated MEG3 has been associated with autophagy and increased cell proliferation in bladder cancer. 17 CpG methylation assays pinpointed that MEG3 hypermethylation impacts overall survival in patients with acute myeloid leukemia (AML). 18 Another p53-regulated lncRNA is the co-activator of p21 expression, lincRNA-p21. lincRNA-p21 regulates p21 in cis ( tumor formation showed that Neat1 KO mice did not develop chemically-induced skin cancer. 28 Likewise, higher expression correlated with unfavorable prognosis in CRC patients. 29 However, intriguingly, depletion of NEAT1 inhibited cell growth in breast cancer cells. 30 Furthermore, loss of Neat1 in Kras G12D murine models promoted pancreatic precursor lesions and enhanced fibroblast malignant transformation. 31 Therefore, the biological relevance of NEAT1 in tumorigenesis should be clarified before it can be considered to be a therapeutic target. 
| TUMOR DRIVERS
The metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), also called NEAT2, is an abundant and highly conserved lncRNA across vertebrates. It was first described as a prognostic marker for lung adenocarcinoma. 38, 39 MALAT1 is recruited to nuclear speckles, which are dynamic compartments destined to processes of mRNA alternative splicing 40, 41 in breast cancer ER-positive luminal cells showed a reduction in cell proliferation, demonstrating its involvement in tumor progression. 43 The chromatin-associated HuR/MALAT1 functional complex controls CD133 gene expression during the dedifferentiation process of breast cancer cells, both in vitro and in vivo. 44 In the most representative form of ovarian cancer, epithelial ovarian cancer (EOC), MALAT1 induces an epithelial-to-mesenchymal transition (EMT) switch via the PI3K/AKT pathway. 45 In CRC tumor tissues, MALAT1 expression has been reported to be a potential predictor of tumor metastasis and prognosis. 46, 47 Similarly, its implication has been reported in studies of glioma, HCC and prostate cancer, among others. [48] [49] [50] Overall, these findings suggest the possibility that the inhibition of MALAT1 might impair cancer-cell growth, metastasis, or both with minimal side effects, making it a promising candidate of drug-targeted therapeutics (Table 2) .
Another metastasis-associated lncRNA is the HOX antisense intergenic RNA HOTAIR. Genome-wide analysis from CRC patient specimens supported that HOTAIR is involved in tumor promotion and that its decay enhances radio-sensitivity. 51, 52 In breast cancer, it works as a predictive marker for metastatic progression and overall survival in early-stage surgically resected tumors. 53 Of note, emerging studies on the susceptibility of breast cancer have indicated the and HOTAIR, which have been shown to be associated with ERa/ ERb at the chromatin level, display different mechanisms to abrogate the ER response, suggesting a new type of hormone action. 57 The lncRNA NORAD is regulated in the DDR and exerts a key role on chromosomal instability. 58, 59 Whereas NORAD À/À cells develop genomic instability and aneuploidy, the overactivation of NORAD is significantly found in tissues of CRC, esophageal squamous cell carcinoma (ESCC) and bladder cancer, contributing to tumor progression. [59] [60] [61] [62] In an attempt to determine whether a low-copy-number gain of the genes accompanying MYC in the 8q24.21 region generates neoplasia, chromosome engineering was used in mice. These results revealed that high levels of Myc protein are dependent upon lncRNA Pvt1 to promote tumor development and that Myc alone is insufficient otherwise. 63 Concomitantly, PVT1-null CRC cell lines Better pharmacological targeting of cancer-associated lncRNA is a must for understanding their participation at distinct cancer levels. 79 Likewise, the overexpression of PVT1 resulted in an increase of Snail and ZEB1 expression in pancreatic cancer (Figure 2 ). 80 
| CONCLUDIN G REMARKS
Collectively, these studies highlight the importance of lncRNA in the cancer landscape. lncRNA are capable of tuning gene expression and impacting cellular signaling cascades. Occasionally, this impact can be easily seen at the phenotypic level; however, in other cases, it may result in more subtle phenotypes that can solely be detected after comprehensive analysis. The latter must be considered carefully;
based on their translational relevance, the pharmacological targeting of lncRNA that display minor phenotypes upon depletion may represent an opportunity for clinical application.
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